[{"id":"10ef3bfd-4f2b-44e8-8464-dcdb39fd64ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT04499573","created_at":"2021-01-18T21:33:19.864Z","updated_at":"2024-07-02T16:35:54.995Z","phase":"Phase 1/2","brief_title":"Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL","source_id_and_acronym":"NCT04499573","lead_sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","biomarkers":" CD22","pipe":" | ","alterations":" CD19 expression • CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • etoposide IV • fludarabine IV • Actemra IV (tocilizumab) • MB-CAR-T19-22"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/27/2020","start_date":" 07/27/2020","primary_txt":" Primary completion: 03/13/2022","primary_completion_date":" 03/13/2022","study_txt":" Completion: 03/13/2027","study_completion_date":" 03/13/2027","last_update_posted":"2023-02-22"}]